natgillin/translations-raw huggingface dataset:
Memantin Accord tilhører gruppen af medicin kaldet antidemensmedicin (medicin til behandling af demens).
Memantine Accordbelongs to a group of medicines known as anti-dementia medicines.
Memantin Accord10 mg filmovertrukne tabletter er hvide, aflange, overtrukne tabletter med delekærv, præget med ”MT” delt af kærven på den ene side og ”1 0” delt af kærven på den anden side.
Memantine Accord 10mg film-coated tablets are presented as white, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “10” divided by the score on the other side.
Memantin Accord15 mg filmovertrukne tabletter er orange til gråligt orange, aflange, overtrukne tabletter præget med ”MT” delt af kærven på den ene side og ”15” delt af kærven på den anden side.
Memantine Accord 15mg film-coated tablets are presented as orange to grey-orange, oblong, coated tablet, debossed with “MT” on one side and “15” on the other side.
Memantin Accord20 mg filmovertrukne tabletter er svagt røde til gråligt røde, aflange, overtrukne tabletter med delekærv, præget med ”MT” delt af kærven på den ene side og ”20” delt af kærven på den anden side.
Memantine Accord 20mg film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “20” divided by the score on the other side.
Memantin Accord5 mg filmovertrukne tabletter er hvide, aflange overtrukne tabletter præget med ”MT” på den ene side og ”5” på den anden side.
Memantine Accord 5mg film-coated tablets are presented as white, oblong, coated tablet, debossed with “MT” on one side and “5” on the other side.
Memantin Accordanbefales ikke til børn og unge under 18 år.
Memantine Accord is not recommended for children and adolescents under the age of 18years.
Memantin Accordanvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine Accordis used for the treatment of patients with moderate to severe Alzheimer’s disease.
Memantin Accordbør indtages gennem munden én gang dagligt.
Memantine Accord should be administered orally once a day.
Memantin Accordindvirker på disse NMDA- receptorer og forbedrer overførslen af nervesignaler samt hukommelsen.
Memantine Accord acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Memantin Accordtilhører gruppen af medicin kaldet antidemensmedicin (medicin til behandling af demens)..
Memantine Accordbelongs to a group of medicines known as anti-dementia medicines.
Memantin forbedrer signaloverførslen i hjernen ved at blokere NMDA-receptorerne, så symptomerne på Alzheimers sygdom mindskes.
By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer’s disease.
Memantin frarådes hos gravide kvinder.
The use of memantine in pregnant women is not recommended.
Memantin frarådes til gravide kvinder.
The use of memantine in pregnant women is not recommended.
Memantin har en absolut biotilgængelighed på ca.
Memantine has an absolute bioavailability of approximately 100%.
Memantin hæmmede ikke CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin indeholdende monooxygenase, epoxidhydrolase eller sulfatering in vitro.
Memantine did not inhibit CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin containing monooxygenase, epoxide hydrolase or sulphation in vitro.
Memantin hæmmede ikke CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin indeholdende monoxygenase, epoxid hydrolase eller sulfatering in vitro.
Memantine did not inhibit CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin containing monooxygenase, epoxide hydrolase or sulphationin vitro.
Memantin var ikke teratogent hos rotter og kaniner, selv ved maternale toksiske doser, og der blev ikke noteret nogen bivirkninger af memantin i forbindelse med fertilitet.
Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted onf ertility.
Memantin var ikke teratogent hos rotter og kaniner, selv ved maternale toksiske doser, og der blev ikke noteret nogen bivirkninger af memantin i forbindelse med fertilitet.
Memantine was not teratogenic inrats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted on fertility.
Memantine Accord er et “generisk lægemiddel”.
Memantine Accord is a ‘generic medicine’.
Memantine forbedrer signaloverførslen i hjernen ved at blokere NMDA-receptorerne, så symptomerne på Alzheimers sygdom mindskes.
By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer’s disease.
Memantine LEK 10 mg filmovertrukne tabletter Memantine LEK 20 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine LEK 10 mg film-coated tablets Memantine LEK 20 mg film-coated tablets Memantine hydrochloride
Memantine LEK 10 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine LEK 10 mg film-coated tablets Memantine hydrochloride
Memantine LEK 10 mg filmovertrukne tabletter.
Memantine LEK 10 mg film-coated tablets.
Memantine LEK 10mg filmovertrukne tabletter er gul, oval, filmovertrukket tablet med delekærv på den ene side.
Memantine LEK 10 mg film-coated tablets are presented as yellow, oval film-coated tablet scored in one side.
Memantine LEK 10mg filmovertrukne tabletter fås i aluminium/PVC/PVDC-blisterkort i æsker, som indeholder 28, 30, 42, 50, 56, 60, 98, 100 og 112 filmovertrukne tabletter.
Memantine LEK 10 mg film-coated tablets are available in PVC/PVDC–Aluminium blister packs of 28, 30, 42, 50, 56, 60, 98, 100 and 112 tablets.
Memantine LEK 20 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine LEK 20 mg film-coated tablets Memantine hydrochloride
Memantine LEK 20 mg filmovertrukne tabletter.
Memantine LEK 20 mg film-coated tablets.
Memantine LEK 20mg filmovertrukne tabletter fås i aluminium/PVC/PVDC-blisterkort i æsker, som indeholder 28, 30, 42, 56, 98 og 100 filmovertrukne tabletter.
Memantine LEK 20 mg film-coated tablets are available in PVC/PVDC–Aluminium blister packs of 28, 30, 42, 56, 98 and 100 tablets.
Memantine LEK anbefales ikke til børn og unge under 18 år.
Memantine LEK is not recommended for children and adolescents under the age of 18 years.
Memantine LEK anvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine LEK is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Memantine LEK er et "generisk lægemiddel".
Memantine LEK is a ‘generic medicine’.
Memantine LEK er et lægemiddel til behandling af patienter med moderat til svær Alzheimers sygdom, dvs. en type demens (en hjernesygdom), der gradvis påvirker hukommelse, intellektuelle evner og adfærd.
Memantine LEK is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Memantine LEK indvirker på disse NMDA- receptorer og forbedrer overførslen af nervesignaler samt hukommelsen.
Memantine LEK acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Memantine LEK tilhører gruppen af medicin kaldet antidemensmedicin (medicin til behandling af demens)..
Memantine LEK belongs to a group of medicines known as anti-dementia medicines.
Memantine Merz 10 mg filmovertrukne tabletter.
Memantine Merz 10 mg film-coated tablets
Memantine Merz 10 mg, filmovertrukne tabletter.
Memantine Merz 10 mg film-coated tablets.
Memantine Merz 15 mg filmovertrukne tabletter er orange til gråligt orange, ovale-aflange tabletter præget med ”15” på den ene side og ”MEM” på den anden side.
Memantine Merz 15 mg film-coated tablets are presented as orange to grey-orange, oval-oblong with imprint ‘15’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 15 mg, filmovertrukne tabletter.
Memantine Merz 15 mg film-coated tablets.
Memantine Merz 20 mg filmovertrukne tabletter er svagt røde til gråligrøde, ovale-aflange tabletter præget med ”20” på den ene side og ”MEM” på den anden sidet.
Memantine Merz film-coated tablets are presented as pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 20 mg filmovertrukne tabletter er svagt røde til gråligt røde, ovale-aflange tabletter præget med ”20” på den ene side og ”MEM” på den anden sidet.
Memantine Merz 20 mg film-coated tablets are presented as are pale red to grey-red, oval-oblong with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 20 mg filmovertrukne tabletter.
Memantine Merz 20 mg film-coated tablets.
Memantine Merz 20 mg, filmovertrukne tabletter.
Memantine Merz 20 mg film-coated tablets.
Memantine Merz 5 mg filmovertrukne tabletter er hvide til grålighvide, ovale-aflange tabletter præget med ”5” på den ene side og ”MEM” på den anden side.
Memantine Merz 5 mg film-coated tablets are presented as white to off-white, oval-oblong with imprint ‘5’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 5 mg filmovertrukne tabletter.
Memantine Merz 5 mg film-coated tablets.
Memantine Merz 5 mg, 10 mg, 15 mg, 20 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine Merz 5mg, 10mg, 15mg, 20 mg film-coated tablets Memantine hydrochloride
Memantine Merz 5 mg, filmovertrukne tabletter.
Memantine Merz 5 mg film-coated tablets.
Memantine Merz 5 mg/pumpetryk, opløsning.
Memantine Merz 5 mg/pump actuation, oral solution
Memantine Merz 5 mg/pumpetryk, oral opløsning.
Memantine Merz 5mg/pump actuation, oral solution.
Memantine Merz 5 mg/pumpetryk, oral opløsning. memantinhydrochlorid.
Memantine Merz 5 mg/pump actuation, oral solution memantine hydrochloride
Memantine Merz 5 mg/pumpetryk, oralopløsning. memantinhydrochlorid.
Memantine Merz 5 mg/pump actuation, oral solution Memantine hydrochloride
Memantine Merz anvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine Merz is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Memantine Merz anvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine Merz is used to treat patients with moderate to severe Alzheimer’s disease.
Memantine Merz blev anvendt i tre hovedundersøgelser med i alt 1 125 patienter med Alzheimers sygdom, hvoraf nogle tidligere havde fået anden medicin mod sygdommen.
Memantine Merz has been studied in three main studies including a total of 1,125 patients with Alzheimer’s disease, some of whom had taken other medicines for their disease in the past.
Memantine Merz bør indtages gennem munden en gang pr. dag.
Memantine Merz should be administered orally once a day.
Memantine Merz bør normalt ikke bruges til gravide kvinder.
Pregnancy: The use of memantine in pregnant women is not recommended.
Memantine Merz filmovertrukne tabletter er bleggule til gule, ovale, filmovertrukne tabletter med delekærv og præget ”1-0” på den ene side og ”M M” på den anden side.
Memantine Merz film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side
Memantine Merz filmovertrukne tabletter fås i blisterpakninger med 14 tabletter, 28 tabletter, 42 tabletter, 56 tabletter eller 98 tabletter og multipakninger med 840 (20 x 42) tabletter.
Memantine Merz film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 42 tablets, 56 tablets, 98 tablets or in multipacks of 840 (20 x 42) tablets
Memantine Merz indeholder det aktive stof memantinhydrochlorid
Memantine Merz contains the active substance memantine hydrochloride.
Memantine Merz indvirker på disse NMDA- receptorer og forbedrer overførslen af nervesignaler samt hukommelsen.
Memantine Merz acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Memantine Merz oral opløsning fås i flasker med 50 ml eller 100 ml og multipakninger med 500ml (10 x 50 ml).
Memantine Merz oral solution is available in bottles of 50 ml, 100 ml or a multipack of 500ml (10 x 50 ml).
Memantine Merz skal tages én gang dagligt på samme tidspunkt hver dag.
Memantine Merz should be administered once a day and should be taken at the same time every day.
Memantine Merz var mere effektivt end placebo til at begrænse symptomerne på Alzheimers sygdom.
Memantine Merz was more effective than placebo at controlling the symptoms of Alzheimer’s disease.
Memantine MerzMemantine Merz 10 mg 7 filmovertrukne tabletter.
Memantine Merz 10 mg 7 film-coated tablets.
Memantine MerzMemantine Merz 15 mg 7 filmovertrukne tabletter.
Memantine Merz 15 mg 7 film-coated tablets.
Memantine MerzMemantine Merz 20 mg
Memantine Merz 20 mg
Memantine MerzMemantine Merz 5 mg 7 filmovertrukne tabletter.
Memantine Merz 5 mg 7 film-coated tablets.
Memantine MerzMemantine Merz 5 mg, filmovertrukne tabletter Memantine MerzMemantine Merz 10 mg, filmovertrukne tabletter Memantine MerzMemantine Merz 15 mg, filmovertrukne tabletter Memantine MerzMemantine Merz 20 mg, filmovertrukne tabletter Memantinhydrochlorid
Memantine Merz 5 mg film-coated tablets Memantine Merz 10 mg film-coated tablets Memantine Merz 15 mg film-coated tablets Memantine Merz 20 mg film-coated tablets Memantine hydrochloride
Memantine MerzMemantine Merz 5 mg, Memantine MerzMemantine Merz 10 mg Memantine MerzMemantine Merz 15 mg Memantine MerzMemantine Merz 20 mg
Memantine Merz 5mg, Memantine Merz 10 mg Memantine Merz 15 mg Memantine Merz 20 mg
Memantine MerzMemantine Merz 5 mg, Memantine MerzMemantine Merz 10 mg Memantine MerzMemantine Merz 15 mg Memantine MerzMemantine Merz 20 mg Filmovertrukne tabletter
Memantine Merz 5mg, Memantine Merz 10 mg Memantine Merz 15 mg Memantine Merz 20 mg film-coated tablets
Memantine Mylan anvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine Mylan is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Memantine Mylan bør indtages gennem munden en gang pr. dag.
Memantine Mylan should be administered orally once a day.
Memantine Mylan er et "generisk lægemiddel".
Memantine Mylan is a ‘generic medicine’.
Memantine Mylan er et lægemiddel til behandling af patienter med moderat til svær Alzheimers sygdom, dvs. en type demens (en hjernesygdom), der gradvis påvirker hukommelse, intellektuelle evner og adfærd.
Memantine Mylan is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Memantine Mylan frarådes til børn og teenagere under 18 år.
Memantine Mylan is not recommended for children and adolescents under the age of 18 years.
Memantine Mylan hører til en gruppe af lægemidler kaldet NMDA-receptor-antagonister.
Memantine Mylan belongs to a group of medicines called NMDA- receptor antagonists.
Memantine Mylan indeholder det aktive stof mamantin.
Memantine Mylan contains the active substance memantine.
Memantine ratiopharm 10 mg filmovertrukne tabletter
Memantine ratiopharm 10 mg film-coated tablets
Memantine ratiopharm 10 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine ratiopharm 10 mg film-coated tablets Memantine hydrochloride
Memantine ratiopharm 10 mg filmovertrukne tabletter.
Memantine ratiopharm 10 mg film-coated tablets
Memantine ratiopharm 15 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine ratiopharm 15 mg film-coated tablets Memantine hydrochloride
Memantine ratiopharm 20 mg filmovertrukne tabletter
Memantine ratiopharm 20 mg film-coated tablets
Memantine ratiopharm 20 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine ratiopharm 20 mg film-coated tablets Memantine hydrochloride
Memantine ratiopharm 20 mg filmovertrukne tabletter.
Memantine ratiopharm 20 mg film-coated tablets
Memantine ratiopharm 5 mg filmovertrukne tabletter Memantine ratiopharm 10 mg filmovertrukne tabletter Memantine ratiopharm 15 mg filmovertrukne tabletter Memantine ratiopharm 20 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine ratiopharm 5 mg film-coated tablets Memantine ratiopharm 10 mg film-coated tablets Memantine ratiopharm 15 mg film-coated tablets Memantine ratiopharm 20 mg film-coated tablets Memantine hydrochloride
Memantine ratiopharm 5 mg filmovertrukne tabletter Memantinhydrochlorid
Memantine ratiopharm 5 mg film-coated tablets Memantine hydrochloride
Memantine ratiopharm 5 mg Memantine ratiopharm 10 mg Memantine ratiopharm 15 mg Memantine ratiopharm 20 mg filmovertrukne tabletter
Memantine ratiopharm 5 mg Memantine ratiopharm 10 mg Memantine ratiopharm 15 mg Memantine ratiopharm 20 mg film-coated tablets
Memantine ratiopharm anbefales ikke til børn og unge under 18 år.
Memantine ratiopharm is not recommended for children and adolescents under the age of 18 years.
Memantine ratiopharm anvendes til behandling af patienter med moderat til svær Alzheimers sygdom.
Memantine ratiopharm is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Memantine ratiopharm bør ikke anvendes til børn under 18 år pga. manglende dokumentation for sikkerhed og virkning.
Memantine ratiopharm is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Memantine ratiopharm er et "generisk lægemiddel".
Memantine ratiopharm is a ‘generic medicine’.
Memantine ratiopharm gives én gang om dagen og bør indtages på samme tidspunkt hver dag.
Memantine ratiopharm should be administered once a day and should be taken at the same time every day.
Memantine ratiopharm indeholder lactose og sojalecithin
Memantine ratiopharm contains lactose and soya lecithin
Memantine ratiopharm kan måske også påvirke Deres reaktionsevne, så det ikke er hensigtsmæssigt at føre motorkøretøj eller betjene maskiner.
Also, Memantine ratiopharm may change your reactivity, making driving or operating machinery inappropriate.
Memantine ratiopharm memantinhydrochlorid
Memantine ratiopharm memantine hydrochloride
Memantine ratiopharm tilhører gruppen af medicin kaldet antidemensmedicin (medicin til behandling af demens).
Memantine ratiopharm belongs to a group of medicines known as anti-dementia medicines.
Membranøs glomerulonephritis
Ecchymosis
Men alt i alt er de foreliggende data om risikoen for myokardieiskæmi inkonklusive (se afsnit 4.8).
However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
Men alt i alt er de foreliggende data om risikoen for myokardieiskæmi inkonklusive (se afsnit 4.8).
in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
Men alt i alt er deforeliggende data om risikoen for myokardieiskæmi inkonklusive (se afsnit 4.8).
in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
Men da det er påvist, at M-M-RVAXPRO har samme sikkerheds- og immunogenicitetsprofil som den tidligere formulering af den kombinerede mæslinge-, parotitis- og rubellavaccine fremstillet af Merck & Co., Inc., kan erfaringen med denne vaccine tages i betragtning.
However, since M-M-RVAXPRO has been shown to have safety and immunogenicity profiles similar to the previous formulation of the combined measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., experience with this vaccine can be considered.
Men der er en teoretisk risiko for, at det diende barn kan få alvorlige bivirkninger af Betaferon.
However, it is theoretically possible that a breast-fed baby could experience serious side effects to Betaferon.
Men der er en teoretisk risiko for, at det diende barn kunne få alvorlige bivirkninger af Betaferon.
However, it is theoretically possible that a breast-fed baby could experience serious side effects to Betaferon.
Men der sås ingen testikelændringer i hundestudier med op til 39 ugers varighed ved en eksponering, der var 35 gange det til mennesker ud fra AUC.
However no testicular changes were observed in dog studies of up to 39 weeks duration at an exposure 35–fold that seen in humans based on AUC.
Men det er ukendt, om disse 2 patologier er hyppigere under behandling med somatropin eller ej.
But it is unknown if these 2 pathologies are more frequent or not while treated with somatropin.
Men det skal adskilles fra hæmeolytiske anæmi, der hyppigt forekommer, når der er et forhøjet serum frit kobber i en ukontrolleret Wilson´s sygdom.
However, they must be distinguished from haemolytic anaemia which commonly occurs where there is elevated serum free copper in uncontrolled Wilson’s disease.
Men det tilrådes at vente og se, hvordan du har det, når du har taget Nivestim, før du fører motorkøretøj eller betjener maskiner.
However, it is advisable to wait and see how you feel after taking Nivestim and before driving or operating machinery.
Men eftersom hovedundersøgelsen havde til formål at undersøge lægemidlets virkninger på testosteronkoncentrationer, frem for direkte på kræften eller behandlingsresultatet for patienten, og da leuprorelin kun anvendes til fremskreden prostatakræft, besluttede udvalget at begrænse brugen af Firmagon til fremskreden prostatakræft.
However, because the main study looked at the medicine’s effects on testosterone levels rather than the cancer or the patient’s outcome directly, and because leuprorelin is only used for prostate cancer that is advanced, the Committee decided to restrict the use of Firmagon to advanced prostate cancer.
Men en lille del (10 - 20 %) af den samlede variabilitet i farmakokinetikken for norelgestromin og EE efter applikation af EVRA kan være forbundet med en eller flere af ovenstående demografiske parametre.
However, only a small fraction (10–20%) of the overall variability in the pharmacokinetics of the norelgestromin and EE following application of EVRA may be associated with any or all of the above demographic parameters.
Men en mindre infektion så som en let infektion i de øvre luftveje eller en lav feber er ikke en kontraindikation for immunisering.
However, the presence of a minor infection, such as a mild upper respiratory tract infection or low- grade fever, is not a contraindication for immunisation.
Men givet alvoren af disse hændelser og antallet af rapporterede tilfælde, blev risikoen for alvorlige gastrointestinale lidelser forbundet med dannelse af sevelamer krystaller betragtet som relevant for den ordinerende læge.
However, given the seriousness of these events and the number of reported cases, the risk of formation of sevelamer crystals associated with serious gastrointestinal disorders was considered relevance to the prescriber.
Men hvis De foretrækker det, kan De klemme huden sammen for at danne en fast overflade til indsprøjtningen (figur 5b).
However, if you prefer, you may pinch the skin to create a firmer surface for your injection (Figure 5b).
Men hvis der er mindre end 4 timer til næste dosis, skal du i stedet overspringe den glemte dosis og fortsætte efter doseringsplanen.
However if it is within 4 hours of the next dose, skip the missed dose and go back to the regular dosing schedule.
Men hvis du under behandlingen får symptomer såsom kulderystelser eller feber, må du ikke køre bil, motorcykel, cykle eller betjene maskiner før, symptomerne er forsvundet.
However, if during treatment you experience symptoms, such as chills or fever, you should not drive or use machines until these symptoms disappear.
Men i det 12 uger lange studie med peritonealdialysepatienter sås lignende reduktioner af iPTH i sammenligning med patienter, der fik kalciumacetat.
In the 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
Men i et 12 uger langt studie med peritonealdialysepatienter sås dog lignende reduktioner af iPTH i sammenligning med patienter, der fik kalciumacetat.
In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
Men i et 12 uger langt studie med peritonealdialysepatienter sås dog lignende reduktioner af iPTH sammenlignet med patienter, der fik kalciumacetat.
In a 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.